Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 6, 2024, covers the 2024 Annual Meeting of Stockholders held by Pulse Biosciences, Inc. The meeting was conducted virtually via live audio webcast.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results.
Material Changes and Corporate Actions
- Director Departure: Director Shelley D. Spray did not stand for reelection. The filing states this decision was not attributable to any disagreement with the Company regarding operations, policies, or practices.
- Election of Directors: Five nominees were elected to serve until the 2025 Annual Meeting. All nominees received significant majority support.
- Accounting Firm Ratification: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Voting Results
| Proposal | For | Against | Abstained | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (All 5 Nominees) | 39.5M - 40.7M | 62.9K - 1.2M | 412 - 5.2K | 9,270,519 |
| Ratification of Auditor | 50,006,220 | 5,763 | 18,804 | N/A |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the strategic rationale for Director Shelley D. Spray's departure, despite the filing stating no disagreement occurred.
- Confirm the specific terms of the engagement with Deloitte & Touche LLP for the 2024 fiscal year.
- Review the full proxy statement for detailed biographical information on the newly elected directors.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.